New drug submissions in Canada and a comparison with the Food and Drug Administration and the European Medicines Agency: Cross-sectional analysis.
<h4>Background</h4>Health Canada posts the outcomes of all New Drug Submissions. In some cases, companies have withdrawn submissions or submissions have been rejected by Health Canada for new active substances (NAS). This study explores the reasons for those decisions and compares them w...
Main Author: | Joel Lexchin |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2023-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0286802 |
Similar Items
-
A comparison of the Food and Drug Administration’s and Health Canada’s regulatory decisions about failed confirmatory trials for oncology drugs: an observational study
by: Joel Lexchin
Published: (2021-12-01) -
Information about confirmatory studies required for new drugs conditionally approved by Health Canada: A cross-sectional study
by: Joel Lexchin
Published: (2022-01-01) -
Information about confirmatory studies required for new drugs conditionally approved by Health Canada: A cross-sectional study.
by: Joel Lexchin
Published: (2022-01-01) -
Quality and quantity of data used by Health Canada in approving new drugs
by: Joel Lexchin, et al.
Published: (2023-11-01) -
Comparison of hydroxyethyl starch regulatory summaries from the Food and Drug Administration and the European Medicines Agency
by: Christian J. Wiedermann, et al.
Published: (2017-12-01)